The front row at Amiri included Maluma, Octavia Spencer and Quavo, but all eyes were on Mike Amiri’s parents, attending their first Paris Fashion Week. Iranian immigrants who moved to Los Angeles ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...

Families are right to be angry about devastating care failures in Nottingham. Ministers must respond fast The painful familiarity of key themes in Donna Ockenden’s review of maternity care failures ...

Marina is that curiosity, a cult female star making pop music. Unlike most female pop stars of her longevity, she’s never had one of those monster hits that everyone knows. She has no “Poker Face”, ...

The most significant moment of the season was... The 1-0 win at Fulham in May. In front of a huge contingent of away fans at Craven Cottage, the Cherries battled for a crucial win which put them ...

Cogent Biosciences (COGT) is poised for two product launches later this year after the FDA granted priority review for its marketing application for its lead candidate, bezuclastini, for a rare form ...

Nuvalent (NUVL) has secured a U.S. review for its second product in less than a year after the FDA granted priority review for its marketing application targeting the lung cancer therapy neladalkib.

May 21 (Reuters) - Bayer (BAYGn.DE), opens new tab said on Thursday that the U.S. Food ⁠and Drug Administration had accepted its supplemental New Drug Application for finerenone and granted priority ...

The sNDA for sevabertinib is supported by data from the SOHO-01 trial, showing a median duration of response of 11.0 months and a 71% objective response rate in patients with HER2-mutated NSCLC who ...

ISLANDIA, N.Y.--(BUSINESS WIRE)--O2 Investment Partners (www.o2investment.com) announced today that it has partnered with Atlas Asphalt (“Atlas” or the “Company ...

Rocket Pharmaceuticals has offloaded its lucrative FDA rare pediatric disease priority review voucher (PRV), striking a $180 million sale that reflects the high market demand for a speedy FDA review.